Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2019 1
2021 1
2023 2
2024 1
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Exposito F, et al. Among authors: otegui n. Cancer Res. 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. Cancer Res. 2023. PMID: 37311042
ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer.
Gutiérrez M, Zamora I, Iriarte R, Pajares MJ, Yang Q, Qian C, Otegui N, Fernández-Irigoyen J, Santamaría E, Alcala N, Sexton-Oates A, Fernández-Cuesta L, Barajas M, Calvo A, Montuenga LM, Knudsen B, You S, Freeman MR, Encío I, Rotinen M. Gutiérrez M, et al. Among authors: otegui n. Mol Med. 2025 Jun 11;31(1):232. doi: 10.1186/s10020-025-01267-6. Mol Med. 2025. PMID: 40500731 Free PMC article.
DSTYK Inhibition Sensitizes NSCLC to Taxane-Based Chemotherapy.
Echepare M, Picabea B, Arricibita A, Teijeira Á, Pasquier A, Zandueta C, Otegui N, Santamaría E, Fernández-Irigoyen J, Romero O, Sanchez-Cespedes M, Lecanda F, Hernández J, Felip E, Cruz-Bermúdez A, Provencio M, Gentili M, Facchinetti F, Roz L, Montuenga LM, Valencia K. Echepare M, et al. Among authors: otegui n. J Thorac Oncol. 2025 Mar;20(3):345-365. doi: 10.1016/j.jtho.2024.11.003. Epub 2024 Nov 12. J Thorac Oncol. 2025. PMID: 39536877
Dasatinib Remodels the Tumor Microenvironment and Sensitizes Small Cell Lung Cancer to Immunotherapy.
Redin E, Otegui N, Santos M, Leon S, Redrado M, Serrano D, Fernandez de Pierola E, Russo-Cabrera JS, Ferrer I, Olmedo M, Diaz-Lagares A, Houry M, Vicent S, Vilalta A, Mondelo-Macía P, García-González J, León-Mateos L, Gonzalez A, Paz-Ares L, López R, Sanmamed MF, Montuenga L, Calvo A. Redin E, et al. Among authors: otegui n. Cancer Res. 2025 Oct 15;85(20):3910-3929. doi: 10.1158/0008-5472.CAN-24-2772. Cancer Res. 2025. PMID: 40712061
Dual ENPP1/ATM depletion blunts DNA damage repair boosting radioimmune efficacy to abrogate triple-negative breast cancer.
Ruiz-Fernández de Córdoba B, Valencia K, Welch C, Moreno H, Martínez-Canarias S, Zandueta C, Gómez E, Calvo A, Otegui N, Echepare M, Garzón I, Ajona D, Lara-Astiaso D, Guruceaga E, Guembe L, Pío R, Melero I, Vicent S, Pastor F, Martínez-Monge R, Lecanda F. Ruiz-Fernández de Córdoba B, et al. Among authors: otegui n. Signal Transduct Target Ther. 2025 Jun 13;10(1):185. doi: 10.1038/s41392-025-02271-2. Signal Transduct Target Ther. 2025. PMID: 40506449 Free PMC article.
Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study.
Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán … See abstract for full author list ➔ Chaparro M, et al. J Clin Med. 2021 Jun 29;10(13):2885. doi: 10.3390/jcm10132885. J Clin Med. 2021. PMID: 34209680 Free PMC article.
EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain.
Chaparro M, Barreiro-de Acosta M, Benítez JM, Cabriada JL, Casanova MJ, Ceballos D, Esteve M, Fernández H, Ginard D, Gomollón F, Lorente R, Nos P, Riestra S, Rivero M, Robledo P, Rodríguez C, Sicilia B, Torrella E, Garre A, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP; EpidemIBD study group of GETECCU. Chaparro M, et al. Therap Adv Gastroenterol. 2019 May 21;12:1756284819847034. doi: 10.1177/1756284819847034. eCollection 2019. Therap Adv Gastroenterol. 2019. PMID: 31205485 Free PMC article.
11 results